Testing effectiveness (Phase 2)Ended earlyNCT00374296
What this trial is testing
MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease
Who this might be right for
Myelogenous Leukemia, AcuteMyelodysplastic Syndromes
Mirati Therapeutics Inc. 35